Home > Insider Trading > Filing (0001062993-21-002765)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1718852	Prometheus Biosciences Inc.	RXDX	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1164426	Joseph Edelman	51 Astor Place, 10Th Floor New York NY 10003	No	No	Yes	No
1224962	Perceptive Advisors Llc	51 Astor Place, 10Th Floor New York NY 10003	No	No	Yes	No
1249675	Ltd Fund Master Sciences Life Perceptive	51 Astor Place, 10Th Floor New York NY 10003	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-03-16	1,017,770	$0.00	1,017,770	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-03-16	1,446,262	$0.00	2,464,032	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-03-16	850,000	$19.00	3,314,032	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series D-1 Convertible Preferred Stock	Disposition	2021-03-16	10,177,703	$0.00	1,017,770	$0.00
Common Stock	Series D-2 Convertible Preferred Stock	Disposition	2021-03-16	14,462,623	$0.00	1,446,262	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Shares of Series D-1 Preferred Stock and Series D-2 Preferred Stock are convertible at any time, at the holder's election, at a ratio of ten-for-one shares of the Issuer's common stock. Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series D-1 Preferred Stock and Series D-2 Preferred Stock automatically converted at the ratio of ten-for-one shares of the Issuer's common stock. The Series D-1 Preferred Stock and Series D-2 Preferred Stock have no expiration date.
The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.